Moving forward: Human papillomavirus vaccination and the prevention of cervical cancer

Journal of Women's Health

Volumn 16, Issue 9, 2007, Pages 1258-1268

  Vetter, Kathleen M ^a   Geller, Stacie E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADVISORY COMMITTEE; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CHILD CARE; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HEALTH CARE NEED; HEALTH CARE PERSONNEL; HEALTH CARE PRACTICE; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; PARENTAL CONSENT; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; UTERINE CERVIX CANCER; VERRUCA VULGARIS; WART VIRUS;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; ADULT; ALPHAPAPILLOMAVIRUS; CHILD; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 36248951595     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2007.0493     Document Type: Article

References (87)

1. Food and Drug Administration (FDA). FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Available at www.fda.gov/bbs/topics/NEWS/2006/NEW01385.html Accessed May 1, 2007.
2. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1.
3. Advisory Committee on Immunization Practices (ACIP). Vaccines for Children Program - Vaccine to prevent human papillomavirus (HPV) infection. Available at www.cdc.gov/nip/vfc/acip_resolutions/0606hpv.pdf Accessed April 20, 2007.
4. ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet Gynecol 2006;108:699.
5. Friedman LS, Kahn J, Middleman AB, Rosenthal SL, Zimet GD. Human papillomavirus (HPV) vaccine: A position statement of the Society for Adolescent Medicine. J Adolesc Health 2006;39:620.
6. Centers for Disease Control and Prevention (CDC). Recommended immunization schedule for ages 7-18 years. United States, 2007. Available at www.cdc.gov/vaccines/recs/schedules/child-schedule.htm#printable Accessed July 17, 2007.
7. American Academy of Pediatrics (AAP). Prevention of human papillomavirus infection: Provisional recommendations for immunization of females with quadrivalent human papillomavirus vaccine. Available at www.cispimmunize. org Accessed July 17, 2007.
8. Saslow D, Castle PE, Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007;57:7.
9. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3.
10. CDC. HPV and HPV vaccine - Information for healthcare providers. Available at www.cdc.gov/std/hpv/STDFact-HPV-vaccine-hcp.htm Accessed April 20, 2007.
11. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: Incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004;36:6.
12. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813.
13. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12.
14. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999;91:506.
15. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24:S1.
16. Moscicki AB. Impact of HPV infection in adolescent populations. J Adolesc Health 2005;37:S3.
17. Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003;188:555.
18. Serraino D, Carrieri P, Pradier C, et al. Risk of invasive cervical cancer among women with, or at risk for, HIV infection. Int J Cancer 1999;82:334.
19. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003;157:218.
20. American Cancer Society (ACS). Cancer facts and figures, 2007. Available at www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf Accessed April 20, 2007.
21. Leyden WA, Manos MM, Geiger AM, et al. Cervical cancer in women with comprehensive health care access: Attributable factors in the screening process. J Natl Cancer Inst 2005;97:675.
22. Singh GK, Miller BA, Hankey BF, Edwards BK. Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer 2004;101:1051.
23. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: Results from the 2000 National Health Interview Survey. Cancer 2003;97:1528.
24. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645.
25. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004;364:1757.
26. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271.
27. Kahn JA, Bernstein DI. Human papillomavirus vaccines and adolescents. Curr Opin Obstet Gynecol 2005;17:476.
28. The Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915.
29. CDC. Vaccine safety overview. Available at www.cdc.gov/od/science/iso/ general_info/overview.htm Accessed July 17, 2007.
30. Australian Drug Evaluation Committee (ADEC) 251st meeting recommendations. Available at www.tga.gov.au/docs/html/adec/adec0251.htm Accessed July 17, 2007.
31. Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res 2006;66:10229.
32. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006;6:753.
33. Lehtinen M, Apter D, Dubin G, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006;17:517.
34. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28.
35. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004;10:1915.
36. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604.
37. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781.
38. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002;13:631.
39. National Survey of Public Knowledge of HPV, the human papillomavirus. Kaiser Family Foundation. Available at www.kff.org/womenshealth/upload/The- HPV-Test-Coming-Soon-to-a-Doctor-s-Office-Near-You-Is-It-Better-than-the-Pap- Smear-for-Detecting-Cervical-Cancer-Chart-Pack.pdf Accessed May 9, 2007.
40. Tiro JA, Meissner HI, Kobrin S, Chollette V. What do U.S. women know about human papillomavirus (HPV) and cervical cancer? Paper presented at Frontiers in Cancer Prevention Research, Boston, MA, November 12-15, 2006.
41. Friedman AL, Shepeard H. Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: Findings from CDC focus group research and implications for practice. Health Educ Behav 2007;34:471.
42. Zimet GD. Improving adolescent health: Focus on HPV vaccine acceptance. J Adolesc Health 2005;37:S17.
43. Gerend MA, Lee SC, Shepherd JE. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm Dis 2007;34:468.
44. Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: A representative statewide analysis. J Adolesc Health 2007;40:108.
45. Daley MF, Liddon N, Crane LA, et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics 2006;118:2280.
46. Raley JC, Followwill KA, Zimet GD, Ault KA. Gynecologists' attitudes regarding human papilloma virus vaccination: A survey of fellows of the American College of Obstetricians and Gynecologists. Infect Dis Obstet Gynecol 2004;12:127.
47. Riedesel JM, Rosenthal SL, Zimet GD, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol 2005;18:391.
48. Kahn JA, Zimet GD, Bernstein DI, et al. Pediatricians' intention to administer human papillomavirus vaccine: The role of practice characteristics, knowledge, and attitudes. J Adolesc Health 2005;37:502.
49. Anhang R, Stryker JE, Wright TC Jr, Goldie SJ. News media coverage of human papillomavirus. Cancer 2004;100:308.
50. Calloway C, Jorgensen CM, Saraiya M, Tsui J. A content analysis of news coverage of the HPV vaccine by U.S. newspapers, January 2002-June 2005. J Womens Health 2006;15:803.
51. Brandt HM, McCree DH, Lindley LL, Sharpe PA, Hutto BE. An evaluation of printed HPV educational materials. Cancer Control 2005;12:103.
52. CDC. CDC Vaccine price list. Available at www.cdc.gov/vaccines/ programs/vfc/cdc-vac-price-list.htm Accessed July 17, 2007.
53. CDC. VFC: Which children are eligible? Available at www.cdc.gov/ vaccines/programs/vfc/parents/eligiblechildren.htm Accessed July 17, 2007.
54. Gerberding JL. Report to Congress on 317 immunization program. Atlanta, GA: Centers for Disease Control and Prevention, 2007.
55. CDC. Immunization of adolescents. Recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR Recomm Rep 1996;45:1.
56. Rand CM, Shone LP, Albertin C, Auinger P, Klein JD, Szilagyi PG. National health care visit patterns of adolescents: Implications for delivery of new adolescent vaccines. Arch Pediatr Adolesc Med 2007;161:252.
57. Dempsey AF, Davis MM. Overcoming barriers to adherence to HPV vaccination recommendations. Am J Manag Care 2006;12:S484.
58. Zimet GD, Mays RM, Fortenberry JD. Vaccines against sexually transmitted infections: Promise and problems of the magic bullets for prevention and control. Sex Transm Dis 2000;27:49.
59. Zimet GD. Understanding and overcoming barriers to human papillomavirus vaccine acceptance. Curr Opin Obstet Gynecol 2006;18:523.
60. Gonik B. Strategies for fostering HPV vaccine acceptance. Infect Dis Obstet Gynecol 2006. Online only. Article #36797.
61. Hillard PJ, Kahn JA. Understanding and preventing human papillomavirus infection during adolescence and young adulthood. J Adolesc Health 2005;37:S1.
62. Monk BJ, Wiley DJ. Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America? Obstet Gynecol 2006;108:420.
63. Kahn JA. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health 2005;37:S10.
64. Myers ER. HPV vaccines: Now that they're here, how do we maximize their benefit? Contraception 2006;74:277.
65. Curtis CR. HPV vaccine use and recommendations and the U.S. adolescent immunization program. Paper presented at Maternal and Child Health Epidemiology Conference, Atlanta, GA, December 2006.
66. Hinman AR, Orenstein WA. Adult immunization: What can we learn from the childhood immunization program? Clin Infect Dis 2007;44:1532.
67. Infectious Diseases Society of America. Executive summary - Actions to strengthen adult and adolescent immunization coverage in the United States: Policy principles of the Infectious Diseases Society of America. Clin Infect Dis 2007;44:1529.
68. Hinman AR, Orenstein WA, Rodewald L. Financing immunizations in the United States. Clin Infect Dis 2004;38:1440.
69. IOM. Calling the shots: Immunization finance policies and practices. Washington, DC: Institute of Medicine, 2000.
70. Backer H. Implementation issues for HPV vaccine. Paper presented at National Immunization Conference, Kansas City, MO, 2007.
71. The uninsured: A primer. Washington, DC: Kaiser Family Foundation, 2006. Article #7451-02.
72. Merck and Company, Inc. CDC finalizes advisory panel recommendations for Gardasil, Merck's cervical cancer vaccine. Available at www.merck.com/ newsroom/press_releases/product/2007_0322.html Accessed May 1, 2007.
73. Schaffer SJ, Humiston SG, Shone LP, Averhoff FM, Szilagyi PG. Adolescent immunization practices: A national survey of U.S. physicians. Arch Pediatr Adolesc Med 2001;155:566.
74. Rickert D, Deladisma A, Yusuf H, Averhoff F, Brink E, Shih S. Adolescent immunizations. Are we ready for a new wave? Am J Prev Med 2004;26:22.
75. Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. The Task Force on Community Preventive Services. Am J Prev Med 2000;18:97.
76. English A, Kenney KE. State minor consent laws: A summary, 2nd ed. Chapel Hill, NC: Center for Adolescent Health and the Law, 2003.
77. National Conference of State Legislatures (NCSL). HPV vaccine. Available at www.ncsl.org/programs/health/HPVvaccine.htm Accessed July 17, 2007.
78. Averhoff F, Linton L, Peddecord KM, Edwards C, Wang W, Fishbein D. A middle school immunization law rapidly and substantially increases immunization coverage among adolescents. Am J Public Health 2004;94:978.
79. Wilson TR, Fishbein DB, Ellis PA, Edlavitch SA. The impact of a school entry law on adolescent immunization rates. J Adolesc Health 2005;37:511.
80. Orenstein WA, Hinman AR. The immunization system in the United States - The role of school immunization laws. Vaccine 1999;17:S19.
81. Omer SB, Pan WK, Halsey NA, et al. Nonmedical exemptions to school immunization requirements: Secular trends and association of state policies with pertussis incidence. JAMA 2006;296:1757.
82. Should HPV vaccines be mandatory for all adolescents? Lancet 2006;368:1212.
83. Zimmerman RK. Ethical analysis of HPV vaccine policy options. Vaccine 2006;24:4812.
84. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med 2006;355:2389.
85. Lo B. HPV vaccine and adolescents' sexual activity. BMJ 2006;332:1106.
86. American Academy of Family Physicians (AAFP). AAFP policy statement regarding consideration of the mandated use of HPV for school attendance. Available at www.aafp.org/online/en/home/clinical/immunizationres/ mandatedhpv.html Accessed April 25, 2007.
87. Markowitz L. Human papillomavirus: Disease, epidemiology, and vaccine overview. Paper presented at National Immunization Conference, Kansas City, MO, 2007.